Le Lézard
Classified in: Health, Covid-19 virus
Subject: PDT

Pathnostics Launches Single Test to Detect COVID-19, Flu and RSV


IRVINE, Calif., Oct. 28, 2020 /PRNewswire/ -- Pathnostics, a diagnostic solutions company, today announced that it has launched a multiplex polymerise chain reaction (PCR) test that simultaneously detects multiple respiratory infections, including COVID-19, influenzas A/B and respiratory syncytial virus (RSV). It is the company's newest initiative to expand its infectious disease offering as medical experts prepare for the prospect of a "perfect storm" of escalating COVID-19 pandemic cases at the same time as a seasonal influenza epidemic.

"Health officials are warning that we may be facing one of the worst public health periods in modern history with a 'twindemic' of COVID-19 and flu season," said Dr. David Baunoch, co-founder and chief scientific officer, Pathnostics. "We have invested our scientific expertise and diagnostic capabilities to launch this innovative test that quickly and accurately diagnoses all three major respiratory infections anticipated for winter. We're particularly focused on making this test accessible to seniors, a population that is disproportionately at risk of life-threatening repercussions from these viruses."

As U.S. COVID cases surpass 8 million, a recent study published in the Journal of the American Medical Association (JAMA) indicates that one in five COVID-19 patients are experiencing co-infection. Despite many people believing that RSV affects children, the new study reveals that the average age of COVID-19 patients who experience co-infection with RSV is 52 years and with influenza is 74 years. With many of COVID-19's early symptoms presenting similarly as influenza and RSV, Pathnostics' new Respiratory Pathogens Test supports healthcare providers with quickly and accurately diagnosing multiple infections at one time.

Key features of Pathnostics' new test include:
-  Fast turnaround time with results available within 48 hours;
-  Highly accurate results due to molecular-level sensitivity and specificity;
-  A less invasive collection process utilizing a nasal swab inserted into the lower nostril for a more comfortable patient experience;
-  Low or no patient expense with direct billing to insurance and coverage provided by Medicare and Medicaid/Medi-Cal.

To learn more about Pathnostics' new Respiratory Pathogens Test, visit: https://www.pathnostics.com/respiratory-pathogens-test/

About Pathnostics
Pathnostics is a diagnostic solutions company that pioneers innovative approaches for improved patient care. Leveraging its proprietary and patented pooled antibiotic susceptibility (P-ASTTM) testing technology, the company develops and offers a range of diagnostic solutions that address therapeutic issues for physicians and patients. Headquartered in Irvine, Calif., Pathnostics is a company of Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. For more information about the company and its portfolio of products, visit pathnostics.com.

SOURCE Pathnostics


These press releases may also interest you

at 16:35
The Board of Directors of Chimera Investment Corporation announced the declaration of its first quarter cash dividend of $0.11 per common share. The dividend is payable April 30, 2024 to common stockholders of record on April 8, 2024. The ex-dividend...

at 16:30
Apogee Minerals Ltd. ("Apogee" or the "Company" or the "Optionee") has amended the option agreement (the "Amendment Agreement") with Eagle Plains (the "Optionor") whereby the Optionor granted the Company the right to acquire up to an 80% interest in...

at 16:30
Metalla Royalty & Streaming Ltd. ("Metalla" or the "Company") announces its operating and financial results for the year ended December 31, 2023. Metalla has also filed with the U.S. Securities and Exchange Commission (the "SEC") its SEC Annual...

at 16:20
First Trust Advisors L.P. ("FTA") announces the declaration of the Monthly distribution for certain exchange-traded funds advised by FTA, a series of First Trust Exchange-Traded Fund.   The following dates apply to today's distribution...

at 16:20
PACIFIC COAST OIL TRUST (the "Trust"), a royalty trust formed by Pacific Coast Energy Company LP ("PCEC"), announced today that there will be no cash distribution to the holders of its units of beneficial interest of record on March 28, 2024 based...

at 16:20
P3 Health Partners Inc. ("P3" or the "Company") , a patient-centered and physician-led population health management company, today announced its financial results for the fourth quarter and full year ended December 31, 2023, and affirmed its 2024...



News published on and distributed by: